DxNow Revenue and Competitors

Leveraging exclusively-licensed technologies developed in the Demirci Bio-Acoustic MEMS in Medicine Labs (BAMM Labs) at Brigham & Women's Hospital and Stanford University School of Medicine, DxNow, Inc. (www.dxnow.com) is developing sperm separation products to assist clinical practitioners in the selection of healthy motile sperm, with the ultimate objective of enabling improved outcomes for couples undergoing ART procedures. Our fertility products eliminate the need and standardize the process for time-consuming sample preparation and sperm-damaging centrifugation. The result is a simple and fast method, enabling the embryologist to consistently select sperm with higher motility, better morphology, lower ROS generation and lower DNA fragmentation. Founded in 2013, DxNow is a privately-held Delaware C corporation whose corporate headquarters and primary research and development labs are located in Gaithersburg, Montgomery County, Maryland. This location offers close proximity to Washington, DC, the USFDA, USPTO, NIH, CMS and other agencies relevant to DxNow's business interests, as well three major airports. Our mission is to develop and commercialize novel tools that: >Deliver improvements in assisted reproductive technology (ART) in humans and animals >Facilitate faster identification of individuals for prosecution within the criminal justice system >Enable advances in life science research and applied markets >Provide faster, more cost-effective diagnostic solutions for chronically ill patients and their caregivers